Cell Death and Disease (Jun 2021)

Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity

  • Xin Zhang,
  • Can Hu,
  • Xiao-Pin Yuan,
  • Yu-Pei Yuan,
  • Peng Song,
  • Chun-Yan Kong,
  • Teng Teng,
  • Min Hu,
  • Si-Chi Xu,
  • Zhen-Guo Ma,
  • Qi-Zhu Tang

DOI
https://doi.org/10.1038/s41419-021-03922-2
Journal volume & issue
Vol. 12, no. 7
pp. 1 – 12

Abstract

Read online

Abstract Proteasomal activity is compromised in diabetic hearts that contributes to proteotoxic stresses and cardiac dysfunction. Osteocrin (OSTN) acts as a novel exercise-responsive myokine and is implicated in various cardiac diseases. Herein, we aim to investigate the role and underlying molecular basis of OSTN in diabetic cardiomyopathy (DCM). Mice received a single intravenous injection of the cardiotrophic adeno-associated virus serotype 9 to overexpress OSTN in the heart and then were exposed to intraperitoneal injections of streptozotocin (STZ, 50 mg/kg) for consecutive 5 days to generate diabetic models. Neonatal rat cardiomyocytes were isolated and stimulated with high glucose to verify the role of OSTN in vitro. OSTN expression was reduced by protein kinase B/forkhead box O1 dephosphorylation in diabetic hearts, while its overexpression significantly attenuated cardiac injury and dysfunction in mice with STZ treatment. Besides, OSTN incubation prevented, whereas OSTN silence aggravated cardiomyocyte apoptosis and injury upon hyperglycemic stimulation in vitro. Mechanistically, OSTN treatment restored protein kinase G (PKG)-dependent proteasomal function, and PKG or proteasome inhibition abrogated the protective effects of OSTN in vivo and in vitro. Furthermore, OSTN replenishment was sufficient to prevent the progression of pre-established DCM and had synergistic cardioprotection with sildenafil. OSTN protects against DCM via restoring PKG-dependent proteasomal activity and it is a promising therapeutic target to treat DCM.